T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OTIC
2701
DELISTED
Otonomy, Inc.
OTIC
| $128K | ﹤0.01% |
61,400
| – | – |
|
|
KZR
2702
DELISTED
Kezar Life Sciences
KZR
| $127K | ﹤0.01% |
+1,534
| New | +$135K |
|
2703
Perimeter Solutions
PRM
$5.68B
| $126K | ﹤0.01% |
+11,624
| New | +$124K |
|
2704
Curis
CRIS
$3.34M
| $125K | ﹤0.01% |
316
+183
| +138% | +$76.3K |
|
2705
American Superconductor
AMSC
$1.56B
| $124K | ﹤0.01% |
24,000
-2,359
| -9% | -$13.7K |
|
2706
Alaunos Therapeutics
TCRT
$4.88M
| $123K | ﹤0.01% |
663
-216
| -25% | -$20.6K |
|
|
DBD
2707
DELISTED
Diebold Nixdorf Incorporated
DBD
| $123K | ﹤0.01% |
54,341
+18,100
| +50% | +$67.4K |
|
2708
Hippo Holdings
HIPO
$872M
| $122K | ﹤0.01% |
5,556
+3,200
| +136% | +$118K |
|
|
SFR
2709
DELISTED
Appreciate Holdings, Inc. Class A Common Stock
SFR
| $122K | ﹤0.01% |
12,361
| – | – |
|
2710
Westwater Resources
WWR
$75.8M
| $120K | ﹤0.01% |
111,000
+19,500
| +21% | +$25.4K |
|
2711
Kopin
KOPN
$896M
| $119K | ﹤0.01% |
105,900
+57,900
| +121% | +$86.9K |
|
|
DCH
2712
Dauch Corp
DCH
$1.59B
| $118K | ﹤0.01% |
15,611
+2,199
| +16% | +$16.5K |
|
|
AERI
2713
DELISTED
Aerie Pharmaceuticals
AERI
| $118K | ﹤0.01% |
15,715
+4,203
| +37% | +$29.6K |
|
2714
Cytek Biosciences
CTKB
$634M
| $117K | ﹤0.01% |
+10,895
| New | +$108K |
|
2715
EVgo
EVGO
$516M
| $117K | ﹤0.01% |
+19,386
| New | +$184K |
|
2716
US Global Investors
GROW
$38.7M
| $117K | ﹤0.01% |
26,700
| – | – |
|
|
PZN
2717
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $117K | ﹤0.01% |
17,724
+5,285
| +42% | +$36K |
|
2718
Bionano Genomics
BNGO
$13.4M
| $116K | ﹤0.01% |
141
+3
| +2% | +$3.09K |
|
|
VTNR
2719
DELISTED
Vertex Energy, Inc
VTNR
| $115K | ﹤0.01% |
+10,959
| New | +$130K |
|
2720
Lineage Cell Therapeutics
LCTX
$268M
| $114K | ﹤0.01% |
72,400
+11,309
| +19% | +$14.9K |
|
|
ESPR
2721
DELISTED
Esperion Therapeutics
ESPR
| $113K | ﹤0.01% |
17,819
+728
| +4% | +$4.13K |
|
2722
LifeVantage
LFVN
$81M
| $113K | ﹤0.01% |
25,900
| – | – |
|
|
SUP
2723
DELISTED
Superior Industries International
SUP
| $113K | ﹤0.01% |
28,600
| – | – |
|
|
RMO
2724
DELISTED
Romeo Power, Inc.
RMO
| $113K | ﹤0.01% |
251,200
+63,278
| +34% | +$59.3K |
|
2725
Genprex
GNPX
$2.51M
| $112K | ﹤0.01% |
2
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.